Trial Profile
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced nonsquamous non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.